The Peptides & Complex Generics Symposium 2025 in Mumbai brought together leaders pushing the frontier in peptide therapeutics and complex generic drug development.
A clear highlight was the power of in silico approaches. With Modeling & Simulation from AI-powered predictive analytics and PBPK modeling to bioequivalence simulations, InSilicoMinds delivers regulatory-compliant digital dossiers and agile in silico prototyping that streamline formulation optimization, dosing strategies, and risk mitigation from early research through commercial launch.
Global regulators including the FDA, the European Medicines Agency, and the Central Drugs Standard Control Organization are championing model-informed drug development (MIDD), enabling validated models to predict clinical outcomes, reduce trial burden, and speed approvals. For teams building in peptides and complex generics, in silico Modeling & Simulation offers a clear competitive advantage across formulation, dosing, and regulatory strategy.
